Back to Search
Start Over
Anti-tubercular activity evaluation of natural compounds by targeting Mycobacterium tuberculosis resuscitation promoting factor B inhibition: An in silico study.
- Source :
-
Molecular diversity [Mol Divers] 2024 Jun; Vol. 28 (3), pp. 1057-1072. Date of Electronic Publication: 2023 Mar 24. - Publication Year :
- 2024
-
Abstract
- Tuberculosis (TB), an infectious disease caused by the Mycobacterium tuberculosis (Mtb), has been responsible for the deaths of millions of individuals around the globe. A vital protein in viral pathogenesis known as resuscitation promoting factor (RpfB) has been identified as a potential therapeutic target of anti-tuberculosis drugs. This study offered an in silico process to examine possible RpfB inhibitors employing a computational drug design pipeline. In this study, a total of 1228 phytomolecules were virtually tested against the RpfB of Mtb. These phytomolecules were sourced from the NP-lib database of the MTi-OpenScreen server, and five top hits (ZINC000044404209, ZINC000059779788, ZINC000001562130, ZINC000014766825, and ZINC000043552589) were prioritized for compute intensive docking with dock score ≤ - 8.5 kcal/mole. Later, molecular dynamics (MD) simulation and principal component analysis (PCA) were used to validate these top five hits. In the list of these top five hits, the ligands ZINC000044404209, ZINC000059779788, and ZINC000043552589 showed hydrogen bond formation with the functional residue Glu <superscript>292</superscript> of the RpfB protein suggesting biological significance of the binding. The RMSD study showed stable protein-ligand complexes and higher conformational consistency for the ligands ZINC000014766825, and ZINC000043552589 with RMSD 3-4 Å during 100 ns MD simulation. The overall analysis performed in the study suggested promising binding of these compounds with the RpfB protein of the Mtb at its functional site, further experimental investigation is needed to validate the computational finding.<br /> (© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Subjects :
- Computer Simulation
Biological Products pharmacology
Biological Products chemistry
Cytokines metabolism
Ligands
Principal Component Analysis
Mycobacterium tuberculosis drug effects
Antitubercular Agents pharmacology
Antitubercular Agents chemistry
Molecular Docking Simulation
Molecular Dynamics Simulation
Bacterial Proteins antagonists & inhibitors
Bacterial Proteins chemistry
Bacterial Proteins metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1573-501X
- Volume :
- 28
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Molecular diversity
- Publication Type :
- Academic Journal
- Accession number :
- 36964456
- Full Text :
- https://doi.org/10.1007/s11030-023-10632-8